NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/12/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization130.96 mln
Float18.86 mln
Earnings Date09/15/2026
Beneish M-Score
1566
Highly suspicious
1-Year Forecast
7.07
Transformational upside
Relative Strength
12
/ 100
Significantly lagging
Debt / Equity
0.02
Debt-free
ROE
-110
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Founded in 2012 and based in San Diego, California, Connect Biopharma Holdings Limited is working to bring new treatments to patients suffering from conditions where the immune system causes harmful inflammation. Its most advanced drug, rademikibart, blocks a specific protein receptor involved in triggering such reactions and is currently being tested in large-scale clinical trials for atopic dermatitis and asthma.
